Summary
Eli Lilly & Company (LLY) filed an 8-K on April 27, 2021, to report its financial results for the first quarter ended March 31, 2021. The filing includes a press release (Exhibit 99.1) detailing these results, which are being furnished and not formally filed under Section 18 of the Exchange Act. Investors should refer to Exhibit 99.1 for the specific financial performance metrics and operational updates for the quarter. While the 8-K itself is a procedural filing, the attached press release is the primary source of information for investors regarding Lilly's Q1 2021 performance. This includes key financial figures such as revenue, earnings per share, and potentially updates on their product pipeline and strategic initiatives. Investors are encouraged to review the press release for a comprehensive understanding of the company's financial condition and operational results for the period.
Key Highlights
- 1Filing reports Eli Lilly & Company's financial results for the quarter ended March 31, 2021.
- 2Key financial data and operational updates are provided in the attached press release (Exhibit 99.1).
- 3The information furnished is for the period ending March 31, 2021.
- 4The press release is dated April 27, 2021.
- 5The filing is procedural, with the press release being the substantive investor information.
- 6Information is being furnished under Item 2.02 and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- 7Exhibit 104 includes the Cover Page Interactive Data File.